Endo Pharmaceuticals received a "not approvable" letter from the US FDA regarding their supplemental New Drug Application for frovatriptan [Frova]

Author:  

Publisher: Adis International

ISSN: 1173-8324

Source: Inpharma, Vol.1, Iss.1609, 2007-01, pp. : 23-23

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract